Asparkam solution for injection ampoule 5 ml blister No. 10

Pharmacological properties

Pharmacodynamics. Asparkam has antiarrhythmic properties, fills the deficiency of magnesium and potassium ions. Magnesium activates sodium-potassium ATPase, as a result of which the intracellular sodium content decreases and potassium entry into the cell increases. When the sodium concentration in the cell decreases, sodium-calcium metabolism in vascular smooth muscles is inhibited, which leads to their relaxation, potassium ions stimulate the synthesis of ATP, glycogen, proteins, acetylcholine; potassium and magnesium support the polarization of cell membranes. Asparaginate promotes the entry of ions into the cell and participates in energy metabolism. The antiarrhythmic effect is realized due to the ability of the drug to eliminate electrolyte imbalance, reduce myocardial excitability and conductivity.

Pharmacokinetics: Not studied.

Indication

Application

The drug is intended for intravenous administration only. Adults should be administered slowly intravenously by drip - 10-20 ml (the contents of the ampoule should be diluted in 50-100 ml of 5% glucose solution). If necessary, the dose can be repeated after 4-6 hours. The drug is suitable for combination therapy.

The course of treatment is determined by the doctor.

Children. Experience with the drug in children is insufficient, so it is not used in this category of patients.

Contraindication

Side effects

With rapid intravenous administration of the drug, the possibility of symptoms of hyperkalemia, such as nausea, vomiting, diarrhea, paresthesias, and/or hypermagnesemia, such as facial flushing, hyporeflexia, convulsions, feeling of heat, respiratory depression, should be taken into account.

Special instructions

With prolonged use of the drug, it is necessary to monitor the level of potassium and magnesium in the blood, as well as regular monitoring of electrolyte hemostasis indicators and ECG data.

Asparkam, as a potassium and magnesium-containing drug, should be used with caution in patients with myasthenia gravis; in conditions that can lead to hyperkalemia, such as acute dehydration, the most common tissue damage, in particular severe burns. In this category of patients, it is recommended to regularly examine the level of electrolytes in the blood serum.

Since the drug contains sorbitol, patients with hereditary fructose intolerance should not use this drug.

Use during pregnancy and breastfeeding. To date, no danger has been reported when using the drug in this category of patients.

Interactions

Concomitant use of the drug with potassium-sparing diuretics and/or ACE inhibitors increases the risk of developing hyperkalemia.

Overdose

Cases of overdose are unknown. In case of overdose, symptoms of hyperkalemia and hypermagnesemia may be observed.

Symptoms of hyperkalemia: general weakness, paresthesias, bradycardia, paralysis. Extremely high concentrations of potassium in the blood plasma can lead to death from cardiac depression, arrhythmia or cardiac arrest.

Symptoms of hypermagnesemia: nausea, vomiting, drowsiness, hypotension, bradycardia, weakness, slurred speech, double vision. At very high plasma concentrations of magnesium, hyporeflexia, muscle paralysis, respiratory arrest and cardiac arrest may develop.

In case of overdose, it is necessary to cancel K + -, Mg 2+ -aspartate and it is recommended to carry out symptomatic treatment (calcium chloride 100 mg/min i.v., dialysis, if necessary).

Storage conditions

In the original packaging at a temperature not exceeding 25 ° C. Store out of the reach of children.